L19IL2/L19TNF

Phase 2Small molecule

PPhilogen S.p.A.

L19IL2/L19TNF is one of 134 small molecule programs targeting Basal Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

133

Competitors

Pipeline

Status by Indication[3][1]

Indication

Basal Cell CarcinomaActive, not recruiting

Cutaneous Squamous Cell CarcinomaActive, not recruiting

Skin CancerActive, not recruiting

MelanomaActive, not recruiting

Locally Advanced Basal Cell CarcinomaRecruiting

Basal Cell CarcinomaPhase 2

Active, not recruiting

Cutaneous Squamous Cell CarcinomaPhase 2

Active, not recruiting

Skin CancerPhase 2

Active, not recruiting

MelanomaPhase 2

Active, not recruiting

Locally Advanced Basal Cell CarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Roferon-a

Roche

Phase 3

—2

Incomplete Freund's Adjuvant

EEastern Cooperative Oncology Group

Phase 3

20 3

ABI-007

Bristol-Myers Squibb

Phase 3

1 4

Carboplatin/paclitaxel

AstraZeneca

Phase 3

1 5

Methylphenidate Hydrochloride

Takeda

Phase 3

1 6

Vusolimogene Oderparepvec

YYana Najjar

Phase 3

1 7

L19IL2/L19TNF

PPhilogen S.p.A.

Phase 2

1 8

Zelboraf

CConrado Roberto Hoffmann Filho

Preclinical

39 9

Isolated Limb Perfusion

MMemorial Sloan Kettering Cancer Center

Phase 3

2 10

Intron a

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Melanoma

NCT06284590

Q1 2031

Phase 2Not yet recruiting

Basal Cell Carcinoma

NCT07227870

Phase 2Not yet recruiting

Cutaneous Squamous Cell Carcinoma

NCT07228442

Phase 2Recruiting

Locally Advanced Basal Cell Carcinoma

NCT07227350

Clinical

Trials by Indication[1]

Skin Cancer1 trial

L19IL2/L19TNF in Skin Cancer Patients

Unknown status·PPhilogen S.p.A.·Phase 2·NCT05329792·70 enrolled

Basal Cell Carcinoma1 trial

L19IL2/TNF in Patients With Basal Cell Carcinoma

Not yet recruiting·PPhilogen S.p.A.·Phase 2·NCT07227870·92 enrolled

Tumor1 trial

Intratumoral Administration of L19IL2/L19TNF

Completed·PPhilogen S.p.A.·Phase 2·NCT02076633·21 enrolled

Melanoma1 trial

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients

Recruiting·PPhilogen S.p.A.·Phase 2·NCT06284590·162 enrolled

Cutaneous Squamous Cell Carcinoma1 trial

L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma

Not yet recruiting·PPhilogen S.p.A.·Phase 2·NCT07228442·92 enrolled

1 more indication

Locally Advanced Basal Cell Carcinoma1 trial

A Phase 2 Controlled Randomized Study of the Efficacy of L19IL2 or L19TNF or L19IL2/L19TNF Intralesional Injections for the Treatment of Locally Advanced Basal Cell Carcinoma (LaBCC)

Recruiting·PPhilogen S.p.A.·Phase 2·NCT07227350·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for L19IL2/L19TNF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — L19IL2/L19TNF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for L19IL2/L19TNF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Philogen S.p.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPhilogen S.p.A.

L19IL2/L19TNF

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q1 2031

Trials by Indication[1]

Skin Cancer1 trial

Basal Cell Carcinoma1 trial

Tumor1 trial

Melanoma1 trial

Cutaneous Squamous Cell Carcinoma1 trial

Locally Advanced Basal Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News